CN Patent

CN110054596A — 一种取代噁二唑类化合物及其应用

Assigned to Shenyang University of Chemical Technology · Expires 2019-07-26 · 7y expired

What this patent protects

本发明公开了一种结构新颖的取代噁二唑类化合物，如通式I所示：式中各取代基的定义见说明书。通式I化合物具有优异的杀菌活性，在较低剂量下对多种病害尤其是大豆锈病具有良好的防治效果；因此，本发明包括通式I化合物在农业和其它领域中用作杀菌剂的用途。

USPTO Abstract

本发明公开了一种结构新颖的取代噁二唑类化合物，如通式I所示：式中各取代基的定义见说明书。通式I化合物具有优异的杀菌活性，在较低剂量下对多种病害尤其是大豆锈病具有良好的防治效果；因此，本发明包括通式I化合物在农业和其它领域中用作杀菌剂的用途。

Drugs covered by this patent

Paxlovid (Copackaged) (Nirmatrelvir) · Pfizer

Patent Metadata

Patent number: CN110054596A
Jurisdiction: CN
Classification: —
Expires: 2019-07-26
Drug substance claim: No
Drug product claim: No
Assignee: Shenyang University of Chemical Technology
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.